Eli Lilly (NYSE: LLY) partners with Switzerland-based AC Immune (Nasdaq: ACIU) to research and develop the potential treatment for Alzheimer’s disease and other neurodegenerative diseases. Lilly will pay an initial upfront payment of CHF80 million and CHF60 million to AC Immune on achieving near-term development milestones. AC Immune will also receive low double-digit royalties and … Continue reading Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease